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ABSTRACT 
 
Formation of stable secondary structures by oligomers that mimic natural peptides is a key asset 
for enhanced biological response.  3-Peptides with an additional methylene group in their 
backbone are proteolytically stable and fold into stable 14-helical structures in solution.  Here we 
show that oligomeric 3-hexapeptides synthesized from L-aspartic acid monomers (3-peptides 1, 
5a and 6) or homologated 3-amino acids (3-peptide 2), fold into similar stable 14-helical 
secondary structures in solution, except that the former form right-handed 14-helix and the later 
form left-handed 14-helix.  3-Peptides from L-Asp monomers contain an additional amide bond 
in the side chains that provides opportunities for more hydrogen bonding.  However based on the 
NMR solution structures, we found that 3-peptide from L-Asp monomers (1) and from 
homologated amino acids (2) form similar structures with no additional side chain interactions.  
These results suggest that the 3-peptides derived from L-Asp are promising peptide-mimetics that 
can be readily synthesized using L-Asp monomers as well as the right-handed 14-helical 
conformation of these 3-peptides (such as 1 and 6) may prove beneficial in the design of mimics 
for right-handed -helix of -peptides. 
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INTRODUCTION 
Peptidomimetic molecules play a key role in improving the biological response of -
peptides by stabilizing their secondary structure and increasing stability toward proteolysis.1-3  For 
instance, peptide performance has been improved through partial or total replacement of α-amino 
acids with β-amino acids to give /-peptide or -peptides, respectively.4-13  β3-amino acids 
obtained from homologation of -amino acids (3-homo-amino acids)14 or from L-Asp monomers 
(3-amido-amino acids, Scheme 1)15,16 are used for the synthesis of β3-peptides.  β3-amino acids 
obtained from L-Asp monomers contain an additional amide group in the side chain and therefore 
are called 3-amido-amino acids.   
β3-Peptides prepared from 3-homo-amino acids form a characteristic 14-helix secondary 
structure in solution.  Several strategies have been developed to stabilize the 14-helical secondary 
structure of 3-peptides, especially in aqueous environments.  Some of these strategies include salt 
bridge or lactam formation between complementary charged i/i+3 side chains, as well as 
introduction of cyclic residues.17-21  Formation of stable secondary structure in membrane 
mimicking solvents such as 2,2,2-trifluoroethanol (TFE) is also important as several peptides act 
on membrane-bound protein receptors.  We previously found that a β3-hexapeptide (1) synthesized 
from L-Asp monomers formed a stable right handed 14-helix in TFE,22 and replacement of three 
-amino acids with β3-amido amino acids in a -decapeptide led to the discovery of  hydrid 
peptides that were proteolytically stable and displayed better binding to breast cancer cells 
compared to the native -peptide.8  Based on these findings and the ease of synthesis,15 we set out 
to explore the folding behavior, in particular 14-helix formation, in 3-peptides derived from L-Asp 
monomers. 
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RESULTS AND DISCUSSION 
Design and synthesis of 3-peptide 1 analogues.  Seven new analogues of 3-peptide 1 (Figure 
1, 3-6) were designed to study the folding behavior of 3-peptides derived from L-Asp monomers 
in TFE and aqueous conditions.  3-Peptide 1 is a hexapeptide that forms two turns of the 14-helix 
in TFE, and is unstructured in aqueous conditions.22  3-Peptide 1 analogues (3-peptides 3-6) were 
designed to study the minimum length required for 14-helical structure and the effect of salt-bridge 
forming side chains in stabilizing the 14-helical conformation.  A 3-hexapeptide 2 constructed 
from 3-homo-amino acids, with the same side chains as 3-peptide 1, was included in the study 
for comparison. 
The smallest sequences, 3-peptides 3a and 3b, were four-residues long to incorporate one 
turn of the 14-helix.  3-Peptides 4 and 5 were 5-mer and 6-mer, respectively, and each of these 
contained an amino and a carboxylate side chain at positions i and i+3 for potential salt bridge 
formation in the 14-helical conformation.  For all the sequences, the side chains with amine groups 
were either a mimic of Lysine (a analogues) or Ornithine (b analogues).  Different lengths of the 
side chain amine were used to study the effect of side chain length in the formation of ion-pair 
interaction, as side chain lengths can affect the salt-bridge stability in helical conformations in 
aqueous environments.  Finally, 3-hexapeptide 6 with two amino side chains and two carboxylate 
side chains at positions i and i+3 relative to each other was designed to maximize intramolecular 
salt-bridge interaction and folding.  In all peptides, at least one side of the helix is covered by 
aliphatic side chains to allow for intramolecular hydrophobic interactions. 
3-Peptides 3-6 were synthesized on the Rink amide MBHA resin essentially following the 
same procedure as reported for 3-peptide 1, whereas3-peptide 2 was synthesized by coupling 
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commercially available Fmoc-3-homo-amino acids to the Rink amide resin.  3-Peptides 3-6 were 
synthesized using orthogonally protected Fmoc-L-Asp monomers or pre-synthesized Fmoc-3-
amido-amino acids.   
The general structure of Fmoc-3-amido-amino acids is shown in Scheme 1.  Monomeric 
Fmoc-3-amido-amino acids, such as Fmoc-β3amV-OH and Fmoc-β3amL-OH (Figure S1, 
supporting information), were prepared using either solid phase or solution phase synthesis as 
shown in Scheme 1.  Fmoc-β3amK(Boc)-OH and Fmoc-β3amE(tBu)-OH were prepared using solid 
phase synthesis method only and were obtained in 50-52% yields.  The solution phase method gave 
much higher yields (80%) compared to the solid phase method (50-64%). All 3-amino acids were 
characterized by NMR and mass spectrometry, and the purity was assessed by analytical HPLC 
(Figure S1). 
Shorter sequences, 3 and 4, were synthesized by coupling orthogonally protected Fmoc-L-
Asp where the side chain was introduced during the SPPS, while the synthesis of hexapeptides 5 
and 6, utilized pre-synthesized monomeric Fmoc-3-amido-amino acids.  The completed peptide 
sequences were cleaved from the resin followed by purification using RP-HPLC prior to 
characterization by NMR spectroscopy, mass spectrometry and analytical HPLC (Tables S1-S9 
and Figure S2).  All peptides were obtained in good yields (>50%).   
Protected 3-amino acids building blocks (from L-Asp) were prepared to determine if the 
overall yield of long 3-peptides can be increased.  Peptides 5 and 6 were obtained in relatively 
high yields (81-90%) due to the use of 3-amido amino acid monomers (or protected 3-amino 
acids building blocks) instead of orthogonally protected L-Asp.   
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Circular dichroism spectroscopy of β3-peptides in TFE and aqueous conditions.  The solution 
conformation of 3-peptides was evaluated in TFE and water using CD spectroscopy.  The CD 
spectra provide an initial estimate of solution conformation in a relatively short time based on the 
intensity of a negative minimum at 214 nm.  A minimum at 214 nm for 3-peptides is considered 
as a signature for 14-helical conformation and the intensity of the peak is correlated with the 14-
helical content. 
 First we compared the 14-helical folding of the five hexapeptides in TFE, a helix-
stabilizing solvent.23,24.  As shown in Figure 2a, the mean residue ellipticity (MRE) values at 214 
nm were significantly different for the five 3-peptides.  Surprisingly, 1 shows the largest minima 
at 214 nm (θ = -20 x 103) suggesting highest helical structure followed by 3-peptide 6 with the 
next largest minimum (θ = -16 x 103).  The intensity of peaks for hexamers 5a and 5b was on the 
lower side with 5a (lysine side chain) showing better 14-helicity compared to 5b (ornithine side 
chain) suggesting that the length of the side chain forming salt-bridge does have an effect on 
folding, and the salt bridge between Lys and Glu is more stable than that between Orn and Glu.  
This trend is similar to what was observed by Luc Brunsveld and coworkers in a systematic study 
of side-chain to side-chain interacting 3-peptides.  The authors found that in general longer side 
chain lengths (β3-homoLys vs. β3-homoOrn and β3-homoGlu vs. β3-homoAsp) displayed slightly 
better salt bridge stabilization and 14-helix formation.20  In a previous survey on the preferred 
partner for intra--helical salt bridges in proteins of known structure, it was found to that Glutamate 
not aspartate was the preferred partner suggesting that longer side chain lengths lead to better ion-
pair interaction and folded structure.25   
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 3-Peptide 2 also displays a minimum at 214 nm suggesting 14-helix conformation.  The 
MRE values of 3-peptide 2 and other hexamers may not be directly comparable as these have very 
different side chains.  Moreover, it is interesting to note that even though the absolute configuration 
at 3 carbon in 3-peptides derived from homo-amino acids and L-Asp is opposite, both 3-peptides 
(for instance 1 and 2) have the same sign in the minimum at 214 nm attributed to 14-helix in the 
CD spectra.  Most likely this is due to the major contribution from side chain amides in 3-peptides 
prepared from L-Asp monomers.  These peptides can be viewed as -peptides with substituted L-
asparagine residues.  Interestingly, Mathews et al26 observed that the CD spectrum of a fully 
protected 3-hexapeptide, (Boc-[-Asp(OBn)-3-HGlu(Obn)-3-HSer(OBn)]2-OTCE, made from 
L-Asp, homo-Glu, and homo-Ser residues showed an intense maximum at 198 nm, and two 
shoulders (maxima) at 207 and 216 nm suggesting opposite handed helical structure compared to 
3-hexapeptides 1, 5 and 6. 
 Next we compared the 14-helix stability of the two hexamers, (3-peptide 5a and 6) that 
engage in intramolecular salt-bridge interaction, with deceasing TFE concentration (Figures 2b 
and 2c).  For both the peptides, a decrease in the minimum at 214 nm was observed with increase 
in water concentration suggesting a loss of helical conformation.  3-Peptide 5a always maintained 
14-helical conformation (20-100% TFE), except in 100% water.  A minimum at 214 nm was 
observed even in 20% TFE (θ = -5 x 103) and the peak was lost only in water.  3-Peptide 6 
displayed similar behavior to that of 5a in TFE/water mixtures (Figure 2c).  The CD spectra of 3-
peptide 6 in 100% and 50% TFE show characteristic minima at 214 nm with MRE values -16 x 
103 and -12 x 103, respectively.  There is about 25% reduction in the helical content in 50% 
TFE/water compared to 100% TFE.  The spectra show very small peaks in PBC buffer (pH 7.4, 1 
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mM) and only a small shoulder in water suggesting a dramatic decrease in the helical content.  The 
CD spectrum for 6 was performed in PBS buffer at pH 7.4 to ensure that all amine side chains are 
protonated and the carboxylate are deprotonated to enhance salt bridge interactions.  However, the 
peptide was definitely less folded in aqueous conditions despite the presence of two ion-pair 
interactions.  The loss of secondary structure in water could be due to the placement of the charged 
amino acids opposite to the macrodipole.  Macrodipole present in 3-peptides stabilizes secondary 
structures19,27,28 and can be maintained by placing basic amino acids such as Lysine and Ornithine 
near the N-terminus and acidic residues such as Aspartic and Glutamic acid near the C-
terminus.19,20 Nevertheless, 3-peptide 6 forms a stable 14-helix in TFE.  The CD spectra of 3-
peptide 6 at two different concentrations, 200 M and 1 mM, showed similar minima at 214 nm 
and were found to be independent of concentration suggesting that no changes in aggregation state 
occur in this concentration range.  Finally, the CD spectra of 4-mer and 5-mer 3-peptides (3 and 
4) suggested less folded structures compared to the hexamers (Figure S3), and did not show a clear 
signature of 14-helical content.  For such short oligomers, NMR spectroscopy would be required 
for further evaluation of the folded conformation. 
 
NMR solution structure studies of β3-peptides.  To probe the secondary structure of 3-peptides 
1 (previously studied), and 2-6 (Figure 1) in solution, a detailed NMR spectroscopic investigation 
was carried out.  1D NMR of all the eight peptides (2-6) in TFE-d2 (CF3CD2OH) was examined, 
and the presence of a regular secondary structure was indicated by a large dispersion of the 
chemical shifts.  The well dispersed chemical shifts in the amide region allowed assignment of all 
the backbone and side chain protons (see supporting information, Tables S2-S9).  A two-
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dimensional (2D) NOESY experiment was performed for all the peptides, which allowed 
observation of NOEs between protons from residues that are not sequentially adjacent.  
Characteristic 14-helical peaks were observed mainly for 3-peptides 1, 2 and 6.  The NOESY 
spectrum of 3-hexapeptide 2 showed multiple (five out of six possible) long range Hi Hi+3 
(Figure S4a).  Whereas for 3-peptide 6, all possible (six) long range Hi Hi+3 NOEs were 
observed (Figure S4b) suggesting helical conformation in these peptides.  Interestingly, the 
characteristic H1 H4 peaks were also observed for the smallest 4-mer 3-peptide 3a suggesting 
helical conformation (Figure S4b).  These peaks are a hallmark of 14-helical secondary structure. 
The extent of helical folding in different -peptides can be compared using NOE data.  At 
least four NOE patterns involving backbone and side chain protons that are suggestive of a 14-
helix can be compared.  These NOE patterns are NHi Hi+3, NHi Hi+2, Hi Hi+3, and the 
sidechain CH2-i  sidechain NHi+3 (or Hi HSi+3).  As shown in Figure 3, direct comparison of 
these NOEs showed that 3-peptides 1, 2, and 6 have comparable helical conformation in solution 
(TFE).  Despite the presence of two pairs of oppositely charged side chains in 3-peptide 6, the 
NOEs between the side chain protons of the Glu1-Lys4 and Glu2-Lys5 pairs were relatively weak, 
suggesting that adoption of a stable conformation is not driven by formation of salt-bridges.  The 
backbone NOEs, such as for H11 H4 and H12 H4, were much stronger.  Peptide 5a, with 
a single pair of oppositely charged side chains, seems to be the least structured out of the four 
hexapeptides as it showed only two of the Hi Hi+3 NOEs. 
These peptides behaved differently in aqueous conditions.  2D NOESY and TOCSY spectra 
were recorded for 3-peptide 6 in 25 mM phosphate buffer at pH 6.1 and 6.6.  There was little 
chemical shift dispersion, therefore hall mark long-range NOEs for 14-helices could not be 
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identified.  This lack of dispersion suggests that the peptide is not (stably) folded.  All the backbone 
amides, H and H peaks were overlapped.  The -Leu and -Lys side chain shifts were exactly 
overlapped.  The -Glu side chain protons had slightly different shifts.  This may be due to the fact 
that one of the -Glus is the N-terminal residue.  These observations agreed with the CD data as 
the characteristic minima for 14-helix was not observed for the peptides in aqueous conditions.  
The NMR data suggests that the peptides were not aggregated in water as line widths were 
comparable to those observed in the spectra recorded in TFE. 
The three-dimensional structures of 1 (done previously), 2 and 6 were obtained using the 
NOE data and the program CYANA. 29 The input data and structure calculation statistics of 
peptides 2 and 6 are summarized in Tables S10 and S11.  The pdb coordinates of the 20 structures 
obtained from CYANA program were averaged to obtain the final peptide structures in TFE 
(Figure 4).  3-hexapeptides 1 and 6 form a right-handed 14-helical structure with a radius of 2.6 
Å and 4.69 Å rise/turn.  In contrast, the 3-hexapeptide 2 made up of homo-amino acids, forms a 
left-handed 14-helix (Figures 5 and S5).  The difference in the conformation of the two helices 
(right-handed versus left-handed) could be due to the opposite stereochemistry at the 3 carbon in 
the peptide backbone.  The radius and the pitch for the two helices are found to be similar. 
The extra amide bond in the side chain of 3-peptides derived from L-Asp monomers 
provides opportunities for additional hydrogen bonding capabilities and perhaps unprecedented 
secondary structures.  However, we found that the side chain amide bonds in these 3-peptides (1, 
5a, and 6) do not seem to interact much except that for 3-peptide 1 we see a Leu3 side chain O 
to Leu6 side chain N hydrogen bond possible in some structures.  All possible NOEs were 
incorporated into the structure calculations, and clearly there were not enough contacts observed 
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between the i and i+3 side chains to constrain them in a way to give consistent hydrogen bonds in 
the side chains. 
 
CONCLUSIONS 
In summary, we show that 3-peptides can readily be synthesized from L-Asp monomers 
and for the first time compare the solution conformation of 3-peptides synthesized from 3-
homoamino acids and L-Asp monomers.  Both 3-peptides form similar 14-helix structure which 
can be stabilized by salt-bridge interactions of the side chains at i and i+3 positions in conjunction 
with a maintained helix macrodipole.  The 3-hexapeptides reported here with the charged side 
chains (5 and 6) at i and i+3 positions, however, did not have the basic and acidic side chains in 
the correct order to stabilize the helix macrodipole and therefore, did not give stable structures 
compared to the 3-peptide with no salt-bridge interaction (3-peptide 1).  The synthesis of 3-
peptides with charged residues that will maintain the helix macrodipole is currently in progress.  
The findings presented here show that 3-peptides derived from L-Asp will facilitate the design 
and development of peptidomimetics with improved biological properties. 
 
MATERIALS AND METHODS 
Solvents and reagents.  Rink amide methylbenzhydrylamine (MBHA) resin (0.58 mmol/g), 2-
chlorotrityl chloride resin (1.4 mmol/g),  N-α-Fmoc-L-aspartic acid α-allyl ester, Fmoc-Asp(OtBu)-
OH, Boc-L-asparagine, Fmoc-3hLeu-OH, Fmoc-3hLys(Boc)-OH, Fmoc-3hVal-OH, tert-butyl 
N-(4-aminobutyl)carbamate, β-alanine t-butyl ester hydrochloride, 1-hydroxybenzotriazole 
(HOBt), and benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate 
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(BOP) were purchased from NovaBiochem (San Diego, CA).  Isobutylamine, isopropylamine, 
dimethylformamide (DMF), N-methyl morpholine (NMM), trifluoroacetic acid (TFA), and all 
other reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).  Piperidine was 
purchased from Caledon.  All commercial reagents and solvents were used as received.  Silica gel 
for column chromatography was obtained from Rose Scientific Ltd.  Column chromatography was 
performed under slight positive air pressure using silica gel 60 (70-230 mesh). 
 
Equipment.  RP-HPLC purification and analysis were carried out on a Waters (625 LC system) 
HPLC system using auto-injector mode or Varian Prostar HPLC system (Walkersville, MD, USA) 
using manual injector.  Vydac C18 semi-preparative (1 x 25 cm, 5 μm) and analytical (0.46 x 25 
cm, 5 μm) columns were used.  Peptides were detected by UV absorption at 220 nm.  Mass spectra 
were recorded on a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 
Voyager spectrometer (VoyagerTM Elite) or Waters micromass ZQ (Waters Corp., Milford, MA, 
USA) mass spectrometer.  CD measurements were made on an olis CD spectrometer (Georgia, 
USA) at 25 °C in a thermally controlled quartz cell (Hellma, Plainview, NY).  NMR experiments 
were recorded on a Bruker AM-300 spectrometer at the Faculty of Pharmacy and Pharmaceutical 
Sciences (University of Alberta), or on a Varian INOVA 500 MHz NMR spectrometer equipped 
with a triple-resonance HCN Cold Probe with z-axis pulsed field gradients at the Quebec/Eastern 
Canada High Field NMR Centre, McGill University, Montreal, Quebec. pH measurements for all 
buffer solutions were done at 25 °C with a digital SB20 Symphony VWR pH meter using a 
calibration buffer set (Fluka). 
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Peptide Synthesis.  The synthesis of 3-peptide 1 has been reported previously15 and eight 3-
peptides (2-6) were synthesized following the manual Fmoc-solid phase peptide synthesis.  The 
crude peptides were cleaved from the resin by treatment with TFA:TIPS:H2O (96:2:2) cocktail 
mixture with stirring for 2 h.  The crude peptides were purified using semi-preparative RP-HPLC 
prior to characterization by electrospray and/or MALDI-TOF mass spectrometry and analytical 
HPLC (Table S1 and Figure S2).  All eight peptides were also characterized by 1D proton NMR 
(Tables S2-S9). 
3-Peptide 2 was synthesized by coupling Fmoc-3h-amino acids (Fmoc-3hLeu-OH, 
Fmoc-3hLys(Boc)-OH or Fmoc-3hVal-OH) sequentially to the Rink amide MBHA resin using 
BOP and HOBt as coupling reagents.  The syntheses of 3-peptides 3 and 4 followed the same 
procedure as reported for 3-peptide 1 using orthogonally protected Fmoc-L-aspartic acid.15  
Briefly, orthogonally protected L-aspartic acid (Nα-Fmoc-L-aspartic acid α-allyl ester) is coupled 
to the Rink amide MBHA resin using BOP with HOBt.  The side chain allyl group is first removed 
with Pd(PPh3)4 followed by coupling with an amine (for the corresponding side chain).  Next the 
Fmoc group is removed and orthogonally protected L-aspartic acid is coupled to follow the next 
cycle till the sequence is complete. 
The synthesis of 3-peptide 5 was accomplished by coupling monomeric Fmoc-3-amido-
amino acid (Nβ-Fmoc-β3amV-OH) to 3-peptide 4.  For 3-peptide 6, orthogonally protected L-
aspartic acid was coupled to introduce the first two amino acids, and the last four residues were 
coupled as monomeric Fmoc-3-amido-amino acids to complete the sequence.  Monomeric Fmoc-
3-amido-amino acids (Fmoc-β3amV-OH, Fmoc-β3amL-OH, Fmoc-β3amK(Boc)-OH, and Fmoc-
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β3amE(tBu)-OH) were synthesized using solid phase or solution phase synthesis as described 
below. 
 
Solid Phase Synthesis of Fmoc-3-Amido-Amino Acid Monomers.  Orthogonally protected β3-
amido amino acid monomers were synthesized in four steps as shown in Scheme 1.  In a solid 
phase reactor, chlorotrityl resin (74 mg, 0.1 mmol) was suspended in CH2Cl2 (4 mL) for swelling 
for 30 min.  The swelled resin was reacted with a solution of Fmoc-L-aspartic acid α-allyl ester 
(118.6 mg, 3 equiv) and DIPEA (210 μL, 12 equiv) in dry CH2Cl2 for 2 h.  The resin was capped 
by washing with a solution of dry CH2Cl2–MeOH–DIPEA (17:2:1).  The resin was washed with 
DMF (4 x 1 min), DCM (4 x 1 min) and IPA.  Deallylation was carried out in the presence of 
Pd(PPh3)4 (0.08 equiv) and PhSiH3 (8 equiv) in DCM (3 x 35 mins) under nitrogen to remove the 
side chain allyl protection.  Subsequently, the side chain amine (2.5 equiv) was coupled using BOP 
(110 mg, 2.45 equiv), HOBt (33 mg, 2.5 equiv), and NMM (75 uL, 4.5 equiv) in DMF for 5 h.  
Cleavage of the monomer from the resin was done either by treating with 50% TFA/DCM for 30 
min, or with TFE/DCM (20/80%) for 45 min at room temperature. 
 
Synthesis of Nβ-Fmoc-β3amV.  Nβ-Fmoc-β3amV-OH was synthesized using the procedure 
described above.  Isopropylamine was coupled after removal of side chain allyl group and the final 
product was cleaved from the resin using 50% TFA/DCM for 30 min.  The residue was added to 
cold Et2O (40 mL, -78 °C) and centrifuged at 3,500 rpm for 5 min. The Et2O was decanted and the 
pellet was resuspended in cold Et2O (40 mL, -78°C) and centrifugation was repeated three times.  
Again the Et2O was decanted and the pellet was dried with N2 with an overall yield 65%. The purity 
was assessed by analytical HPLC as shown in Figure S1.  1H NMR (300 MHz, CD3OD): δ= 1.06 
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(d, J= 6.7, 6H, (CH3)2CH), 2.6 (m, 2H, CH2COOH), 3.94 (m, 1H, (CH3)2 CH), 4.25 (m, 1H, 
CHCH2O), 4.7 (m, 2H, CHCH2O), 4.6 (t, 1H, CHCH2COOH), 7.2-7.8 (m, 8H, aryl H).  
13C NMR 
(300 MHz, DMSO-d6, CD3OD): δ= 19.93, 40.67, 40.76, 46.51, 50.68, 65.50, 119.76, 124.99, 
126.80, 127.35, 140.52, 143.57, 155.56, 168.8, 172.87, and ES-MS: Calcd. for C22H24N2O5, 
[M+H]+ 397.47; found [M+H]+  397.06. 
 
Synthesis of Nβ-Fmoc-β3amL.  The synthesis of Nβ-Fmoc-β3amL-OH followed the same 
procedure as for Nβ-Fmoc-β3amV-OH, except that isobutylamine was coupled after removal of 
side chain allyl group with an overall yield of 63%.  The purity was assessed by analytical HPLC 
as shown in Figure S1. 1H NMR (300 MHz, CDCl3): δ= 0.96 (d, J=6.6, 6H, (CH3)2CH), 1.85 (m, 
1H, (CH3)2 CH), 2.8 (m, 1H, CH2COOH), 2.9 (m, 1H, CH2COOH), 3.2 (m, 2H, (CH3)2 
CH)CH2NH), 4.2 (m, 1H, CHCH2O), 4.45 (m, 2H, CHCH2O, CHCH2COOH), 7.2-7.8 (m, 8H, 
arylH).  13C NMR (300 MHz, CDCl3):  δ= 19.93, 27.9, 36.9, 46.06, 46.51, 50.68, 65.60, 119.76, 
124.99, 126.8, 127.35, 140.52, 143.57, 155.56, 168.87, 172.8, and ES-MS: Calcd. for C23H26N2O5, 
[M+H]+ 411.47; found [M+H]+ 411.00. 
 
Synthesis of Nβ-Fmoc-β3amK(Boc)-OH.  Nβ-Fmoc-β3amK (Boc)-OH was synthesized using the 
same procedure as described above.  The side chain mimicking lysine was introduced by coupling 
with tert-butyl N-(4-aminobutyl)carbamate after allyl group removal.  Nβ-Fmoc-β3amK (Boc)-OH 
was cleaved from the resin using TFE/DCM (2:8) for 45 min to obtain the monomer with an overall 
of yield 52%.  The purity was assessed by analytical HPLC as shown in Figure S1.  1H NMR (300 
MHz, CDCl3): δ=1.3 (m, 13H, (CH3)3 CH (CH2)2), 2.2-2.4 (m, 2H, CH2COOH), 2.7- 3.1 (m, 4H, 
(NH)CH2 CH2 CH2 CH2NH), 3.7 (m, 4H, CHCH2O, 2H, CHCH2O, CHCH2COOH), 7.2-7.8 (m, 
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8H, aryl H).  13C NMR (300 MHz, CD3OD):  = 26.34, 26.83, 28.26, 40.69, 40.98, 51.04, 77.30, 
119.98, 121.10, 122.17, 123.88, 127.68, 128.88, 129.43, 135.33, 137.36, 139.34, 142.50, 155.52, 
170.93, and ES-MS:  Calcd. C28H35N3O7, [M-H]
- 524.25; found [M-H]- 524. 
 
Synthesis of Nβ-Fmoc-β3amE(tBu)-OH: Nβ-Fmoc-β3amE(tBu)-OH (10) was synthesized using 
the same procedure as described above for Nβ-Fmoc-β3amK (Boc)-OH.  The side chain mimicking 
glutamic acid was introduced by coupling with β-alanine t-butyl ester hydrochloride after allyl 
group removal.  The overall yield was found to be 50%, and the purity was assessed by analytical 
HPLC as shown in Figure S1. 1H NMR (300 MHz, d-DMSO): δ= 1.4 (s, 9H, (CH3)3C), 2.5-2.8 
(m, 4H, CH2COOH, CH2CH2NHCO), 3.6 (m, 2H, CH2CH2NHCO), 4.25-4.4 (m, 4H, CHCH2O, 
CHCH2O, CHCH2COOH), 7.3-7.8 (m, 8H, aryl H). 
13C NMR (300 MHz, d-DMSO):  δ=27, 34.88, 
34.98, 40.34, 46.64, 50.53, 65.77, 79.99, 120.14, 125.28, 127.13, 127.42, 127.68, 140.7, 143.80, 
155.82, 170.76, 171.69, 173.04, and ES-MS: Calcd. for C26H30N2O7, [M-H]
-  481.54; found [M-
H]- 481.20. 
 
Solution Phase Synthesis of Fmoc-3-Amido-Amino Acid Monomers.  β3-am-Val and β3-am-
Leu monomers were also synthesized using solution phase synthesis as illustrated in Scheme 1.  
Fmoc-Asp(OtBu)-OH (412 mg, 1 mmol),  BOP (442 mg, 1.95 equiv) , HOBt (135 mg, 2 equiv) 
and  NMM (200 μL, 4.5 equiv) were weighted into a round bottom flask, and dissolved in 
DMF/DCM (4 mL).  The mixture was stirred for 5 min to activate the carboxyl group, following 
which the amine side chain (isopropylamine or isobutylamine, 5 equiv) was added and the reaction 
mixture was stirred for 24 h at room temperature.  The completion of reaction was monitored using 
TLC.  The reaction mixture was evaporated to give oil as the residue.  The residue was dissolved 
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in EtOAc (10 mL).  The EtOAc was washed with 5% NaHCO3 three times followed by washing 
(3x) with brine (0.9% NaCl solution).  The organic layer was then dried (Na2SO4), filtered, and 
concentrated.  The product was characterized using mass spectrometry.  After confirmation of the 
mass, the precipitate was treated with TFA:TIPS:H2O (96:2:2) cocktail mixture with stirring for 2 
h.  The reaction mixture was then evaporated under vacuum and the product was washed several 
times with diethyl ether.  The precipitate obtained was further characterized with mass 
spectrometry, HPLC, and NMR spectroscopy.  The overall yield was 80.5%.  The product was 
used without further purification. 
 
Circular Dichroism. All CD measurements were made on an Olis CD spectrometer (Georgia, 
USA) at 25 °C in 2 mm path length thermally controlled quartz cell, over 190-260 nm.  All samples 
were prepared in the appropriate solvents immediately prior to recording the spectra (TFE, H2O, 
or PBS).  Spectra represent the average of five scans, and were background-corrected and 
smoothed.  Each peptide was analyzed at concentrations of 100, 200, 250, and 500 μM. Peptide 
concentrations were determined using dry weight of the lyophilized peptide.  Spectra were 
normalized to mean residue ellipticity (deg cm2 dmol-1) using the formula A*M*3298/ (L*C), 
where C is concentration in g/L, M is average molecular weight (g/mol), L is path length of the 
cell.30 
 
Two-dimensional NMR and Structure Elucidation of β3-Peptides 2 and 6.  All 2D NMR 
measurements and structure elucidation was done at Quebec/Eastern Canada High Field NMR 
Centre, McGill University, Montreal, Quebec.  A 1.5 mM sample of peptides 2 or 6 in 100% TFE-
d2 (CF3CD2OH) (Cambridge Isotope Laboratories, Inc.) was prepared for 2D NMR experiments.  
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Sequence specific assignments were established by following the procedures used for -amino acid 
peptides.31  2D TOCSY (60 ms mixing time), COSY and NOESY (mixing time 300 ms) spectra 
were recorded at 10 C on a Varian INOVA 500 MHz spectrometer.  The upper distance restraints 
for 2 and 6 were obtained from a 300 ms mixing time 2D-NOESY recorded at 10 C on a Varian 
INOVA 800 MHz NMR spectrometer, equipped with an HCN cold probe and pulsed-field 
gradients.  Calculation of the complete three-dimensional structure was performed with the 
program CYANA v2.29  The structure calculation statistics for 2 and 6 are summarized in Tables 
S10 and S11, respectively.  The final calculations were started with 200 randomized conformers 
all of which converged to the helical conformation (average backbone RMSD to mean for 200 
structures: 0.54 ± 0.10 Å for 3-peptide 2 and 0.50 ± 0.12 Å for 3-peptide 6).  A bundle of the 20 
lowest energy CYANA conformers were used to represent the NMR structures of 2 and 6 (Figure 
4). 
 
SUPPORTING INFORMATION 
Peptide characterization and data for three-dimensional NMR solution structures of 2 and 6. 
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FIGURE CAPTIONS 
Figure 1.  Structures of the 3-peptides used in this study.  -Peptides 1, 3-6 are derived from -
amido residues, and -peptide 2 is synthesized from -homo residues. 
 
Scheme 1. General pathway of solid phase (top row) and solution phase (bottom row) syntheses of 
Fmoc-3-amido-amino acids from Fmoc-L-Asp. 
 
Figure 2.  Circular dichroism (CD) spectra for 3-hexapeptides (200 M) at 25 ºC showing (a) 1, 
2, 5a, 5b, and 6 in TFE,  (b) 5a in TFE, TFE/water, and aqueous solution, and (C) 6 in TFE, 
TFE/water, aqueous media, and PBC buffer (pH 7.4). 
 
Figure 3. A comparison of the NOE of β3-hexapeptides 1, 2, 5a and 6 (in TFE) are summarized. * 
denotes amide protons not observed due to exchange with solvent and X stands for H protons not 
observed due to overlap with solvent signal. Grey lines indicate ambiguous assignments. 
 
Figure 4.  3D NMR solution structures of -peptides 2 and 6 in TFE.  The top view of the helices 
are shown using stick model (LHS) and overlay of 10 calculated structures (RHS) for 2 (a-b) and 
6 (c-d). 
 
Figure 5.  Solution conformation of -hexapeptides 1 and 2 in TFE showing right-handed 14-
helix for 1 and left-handed 14-helix for 2.  -Peptide 1 has an additional amide group in each side 
chain.  
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Figure 3. A comparison of the NOE of β3-hexapeptides 1, 2, 5a and 6 (in TFE) are summarized. * 
denotes amide protons not observed due to exchange with solvent and X stands for H protons not 
observed due to overlap with solvent signal. Grey lines indicate ambiguous assignments. 
  
27 
 
 
 
 
 
 
Figure 4.  3D NMR solution structures of -peptides 2 and 6 in TFE.  The top view of the 
helices are shown using stick model (LHS) and overlay of 10 calculated structures (RHS) for 2 
(a-b) and 6 (c-d). 
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Figure 5.  Solution conformation of -hexapeptides 1 and 2 in TFE showing right-handed 14-
helix for 1 and left-handed 14-helix for 2.  -peptide 1 has an additional amide group in each side 
chain. 
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